Novartis AG (SWX:NOVN)
120.28
+1.98 (1.67%)
Jun 22, 2026, 5:31 PM CET
Novartis AG Employees
Novartis AG had 75,267 employees as of December 31, 2025. The number of employees decreased by 616 or -0.81% compared to the previous year.
Employees
75,267
Change (1Y)
-616
Growth (1Y)
-0.81%
Revenue / Employee
602.95K CHF
Profits / Employee
144.23K CHF
Market Cap
220.18B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,267 | -616 | -0.81% |
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Jun 30, 2023 | 103,000 | -5,000 | -4.63% |
| Mar 31, 2023 | 103,000 | -7,000 | -6.36% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Sep 30, 2022 | 108,000 | 0 | - |
| Jun 30, 2022 | 108,000 | -1,000 | -0.92% |
| Mar 31, 2022 | 110,000 | 0 | - |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Sep 30, 2021 | 108,000 | -2,000 | -1.82% |
| Jun 30, 2021 | 109,000 | -1,000 | -0.91% |
| Mar 31, 2021 | 110,000 | 1,000 | 0.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Roche Holding AG | 103,249 |
| Alcon | 25,000 |
| Sandoz Group AG | 22,356 |
| Lonza Group AG | 20,000 |
| Sonova Holding AG | 18,590 |
| Straumann Holding AG | 11,821 |
| Galenica AG | 8,427 |
| Galderma Group AG | 7,676 |
Novartis AG News
- 3 days ago - The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs - WSJ
- 3 days ago - U.S. opens tariff probe targeting Germany's drug pricing policies - CNBC
- 6 days ago - Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC - CNBC
- 10 days ago - Novartis (NVS) Advances RNA Therapy Del-Brax in FSHD Trials - GuruFocus
- 10 days ago - Novartis (NVS) Achieves Key Milestone with Rhapsido in CIndU Trial - GuruFocus
- 10 days ago - Novartis' Rhapsido Shows Promise In Chronic Inducible Urticaria - Nasdaq
- 10 days ago - Novartis announces Rhapsido met primary endpoints in RemIND trial - TheFly
- 10 days ago - Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) - GlobeNewsWire